Physician profile
Daniel J Menefee
NPI 1205365913
$5,293.61
in general payments reported to CMS, 2019-2025
37 companies · $1,648 in 2025
The $1,648 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $890 · 2022: $390 · 2023: $782 · 2024: $1,583 · 2025: $1,648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,013.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $950.42 | 2023-2025 | Provenge |
| Astellas Pharma US INC | $579.91 | 2021-2025 | Myrbetriq, Xtandi |
| Sumitomo Pharma America, INC. | $432.55 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $373.83 | 2021-2025 | |
| Urogen Pharma, INC. | $272.86 | 2022-2024 | Jelmyto |
| Abbvie INC. | $249.03 | 2021-2025 | |
| Olympus America INC. | $224.87 | 2023-2025 | Itind System |
| Endo USA, INC. | $222.35 | 2024-2025 | Xiaflex, Aveed |
| Endo Pharmaceuticals INC. | $215.47 | 2021-2024 | Xiaflex, Aveed, Edex |
| Immunitybio, INC. | $202.55 | 2025 | |
| Tolmar, INC. | $168.54 | 2023-2025 | Jatenzo, Rubraca, Eligard |
| Janssen Biotech, INC. | $122.02 | 2021-2025 | Erleada, Akeega, Balversa |
| Blue Earth Diagnostics | $116.94 | 2021-2022 | |
| Urovant Sciences INC | $110.40 | 2021-2022 | |
| Accord Healthcare, INC. | $95.16 | 2022-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $90.92 | 2022-2025 | Pylarify |
| Astrazeneca Pharmaceuticals Lp | $88.71 | 2021-2025 | Lynparza, Imfinzi |
| Amgen INC. | $76.47 | 2021-2023 | Xgeva |
| Janssen Scientific Affairs, LLC | $74.40 | 2024 | Erleada |
| Verity Pharmaceuticals INC. | $71.36 | 2023-2025 | Trelstar, Tlando |
| Boston Scientific Corporation | $71.27 | 2025 | General - Kidney Stone Disease |
| Teleflex LLC | $69.96 | 2021-2025 | Urolift, Barrigel |
| Tolmar Pharmaceuticals, INC. | $62.74 | 2021-2022 | |
| Antares Pharma, INC. | $53.20 | 2025 | Xyosted |
| Laborie Medical Technologies Corp. | $45.75 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Myovant Sciences INC. | $43.53 | 2021 | |
| Pharmaand Gmbh | $34.83 | 2025 | Rubraca |
| Sun Pharmaceutical Industries INC. | $26.40 | 2025 | |
| Travere Therapeutics, INC. | $23.95 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $17.86 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.00 | 2023 | |
| Procept Biorobotics Corporation | $16.28 | 2022 | |
| Merck Sharp & Dohme LLC | $16.04 | 2024 | Keytruda |
| Clarus Therapeutics INC. | $15.97 | 2021 | |
| Calyxo, INC. | $13.53 | 2024 | Cvac Aspiration System |
| Ferring Pharmaceuticals INC. | $13.49 | 2025 | Adstiladrin |
| E.R. Squibb & Sons, L.L.C. | $13.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Menefee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.